The BayMedica Platform

At BayMedica, we’ve developed a patent-pending precision-fermentation manufacturing platform that transforms common brewer’s yeast into a biological factory for rare cannabinoids. Complementing this fermentation approach with our expertise in synthetic chemistry, we provide a supply chain solution for cannabinoids that are impractical to produce from plants. Our methods enable access to powerful rare cannabinoids with precise dosages and ratios, meeting the growing demand for high-quality, cost-effective rare cannabinoids across multiple industries.

Harnessing the Power of Cannabinoids

Nature’s Limitations:
The Cannabis sativa plant is an impractical source for certain in-demand rare cannabinoids. While compounds like THC and CBD are found in relatively small amounts, the real challenge lies in the separation and extraction of specific minor cannabinoids like CBDV from CBD. Additionally, cannabinoids such as D9-THCV are typically found in plants legally classified as marijuana, which cannot cross state lines and are subject to regulatory restrictions. Our innovative manufacturing approaches overcome these impracticalities, providing a reliable, nature-identical, efficient supply of high-quality rare cannabinoids.

Our Solutions: Biosynthesis and Chemical Synthesis
We leverage common tools in the modern biotechnology industry, specifically biosynthesis and chemical synthesis, to make nature-identical minor cannabinoids. We’ve used both chemistry and engineered common yeast to convert simple sugars into a wide range of cannabinoids, including common and rare natural varieties, as well as novel cannabinoid analogs with pharmaceutical potential. For the minor cannabinoids we make commercially, these processes are often far more efficient than traditional plant cultivation and extraction methods and also tend to yield a cleaner/higher purity product profile than the semi-synthesis of cannabinoids from plant-based starting materials.

Versatile Applications:
Our high-purity, scalable minor cannabinoids have diverse applications across multiple industries, including health and wellness, food and beverage, personal care, cosmetics, and pet care applications. By harnessing the power of biosynthesis and complementing it with our expertise in synthetic chemistry, we can produce a consistent supply of novel cannabinoid analogs and rare cannabinoids. This opens up new possibilities for product innovation across various sectors, providing manufacturers with reliable access to these valuable compounds.

  • Consistent & Pure 100% 100%

Our products are made through a consistent, reproducible process that results in greater purity and consistency than attained by extracting plant material.

  • Regulatory Compliance 100% 100%

Our proprietary platform enables the benefits of cannabis without touching the plant.

  • Rare & Analog Cannabinoids 100% 100%

We can produce common and rare cannabinoid compounds as well as analog compounds not present in the plant.

  • Scalable & Cost Effective 100% 100%

The BayMedica method allows for scalable, cost effective cannabinoid production.

  • Environmentally Friendly 100% 100%

Our method is environmentally sustainable, free of pesticides, fertilizers, mold and heavy metals using enclosed bioreactors.

  • Market Specific Solutions 100% 100%

BayMedica cannabinoids can be tailored for pharmaceutical, nutraceutical, cosmetic, consumer and animal health markets.

Our Biosynthesis Platform & Process

Growth

Our team of scientists transforms common brewer’s yeast into a biological factory to produce pure individual bioidentical cannabinoids from simple sugars. Because the process does not involve plant cultivation and extraction, there are no toxic chemicals, pesticides or heavy metals that are commonly found in cannabis and hemp extracts.

Separation

After several days of fermentation the yeast turns the sugars into significant quantities of the target cannabinoid.

Using a proprietary process we separate the yeast cells from the broth to prepare for purification of the cannabinoid.

Purification & Concentration

The next step in the process is purifying the cannabinoid from the yeast cell. Unlike extraction of cannabinoids from plants, where toxins, fertilizers and heavy metals can come along for the ride, our proprietary technique gently separates and concentrates the cannabinoid.

Natural & Pure Cannabinoids

The result of step three is pure, natural cannabinoids that are identical to the cannabinoid found in the plant. Unlike traditional extraction methods, our process also allows for the production of rare cannabinoids that are found in tiny quantities in the plant.

These pure cannabinoids are then used to produce consumer products such as cannabichromene (CBC), tetrahydrocannabivarin (THCV), cannabidivarin (CBDV), and cannabicitran (CBT).

Novel Cannabinoid Analogs

The BayMedica platform also facilitates the production of novel cannabinoid analogs. These compounds are related to naturally occurring cannabinoids, but have been modified to create new chemical entities for novel pharmaceutical development.

Cannabinoid Analogs

Discover the Future of Cannabinoids